Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1988 1
1994 1
2000 1
2007 1
2009 1
2012 1
2013 1
2014 3
2015 2
2016 6
2017 1
2018 2
2019 2
2020 3
2022 4
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.
Shepherd JH, Ballman K, Polley MC, Campbell JD, Fan C, Selitsky S, Fernandez-Martinez A, Parker JS, Hoadley KA, Hu Z, Li Y, Soloway MG, Spears PA, Singh B, Tolaney SM, Somlo G, Port ER, Ma C, Kuzma C, Mamounas E, Golshan M, Bellon JR, Collyar D, Hahn OM, Hudis CA, Winer EP, Partridge A, Hyslop T, Carey LA, Perou CM, Sikov WM. Shepherd JH, et al. J Clin Oncol. 2022 Apr 20;40(12):1323-1334. doi: 10.1200/JCO.21.01506. Epub 2022 Jan 19. J Clin Oncol. 2022. PMID: 35044810 Free PMC article. Clinical Trial.
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).
Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis CA, Winer EP. Sikov WM, et al. J Clin Oncol. 2015 Jan 1;33(1):13-21. doi: 10.1200/JCO.2014.57.0572. Epub 2014 Aug 4. J Clin Oncol. 2015. PMID: 25092775 Free PMC article. Clinical Trial.
PATIENTS AND METHODS: Patients (N = 443) with stage II to III TNBC received paclitaxel 80 mg/m(2) once per week (wP) for 12 weeks, followed by doxorubicin plus cyclophosphamide once every 2 weeks (ddAC) for four cycles, and were randomly assigned to concurrent carboplatin …
PATIENTS AND METHODS: Patients (N = 443) with stage II to III TNBC received paclitaxel 80 mg/m(2) once per week (wP) for 12 weeks, fo …
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Loibl S, O'Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, Huober J, Golshan M, von Minckwitz G, Maag D, Sullivan D, Wolmark N, McIntyre K, Ponce Lorenzo JJ, Metzger Filho O, Rastogi P, Symmans WF, Liu X, Geyer CE Jr. Loibl S, et al. Lancet Oncol. 2018 Apr;19(4):497-509. doi: 10.1016/S1470-2045(18)30111-6. Epub 2018 Feb 28. Lancet Oncol. 2018. PMID: 29501363 Clinical Trial.
Patients aged 18 years and older with previously untreated histologically or cytologically confirmed clinical stage II-III triple-negative breast cancer, who were candidates for potentially curative surgery and had an Eastern Cooperative Oncology Group performance status of 0 or …
Patients aged 18 years and older with previously untreated histologically or cytologically confirmed clinical stage II-III triple-negative b …
The source parameters, surface deformation and tectonic setting of three recent earthquakes: thessalonki (Greece), tabas-e-golshan (iran) and carlisle (u.k.).
King G, Soufleris C, Berberian M. King G, et al. Disasters. 1981 Mar;5(1):36-46. doi: 10.1111/j.1467-7717.1981.tb01127.x. Disasters. 1981. PMID: 20958479
Both field studies and waveform studies suggest a low stress drop which may explain the relatively little damage and loss of life as a result of the Thessaloniki earthquake. In contrast, the teleseismic moment of the Tabas-e-Golshan earthquake (Force moment 4.4 times 10(26 …
Both field studies and waveform studies suggest a low stress drop which may explain the relatively little damage and loss of life as a resul …
Air Surveillance for Viral Contamination with SARS-CoV-2 RNA at a Healthcare Facility.
Zahedi A, Seif F, Golshan M, Khammar A, Rezaei Kahkha MR. Zahedi A, et al. Food Environ Virol. 2022 Dec;14(4):374-383. doi: 10.1007/s12560-022-09524-1. Epub 2022 May 24. Food Environ Virol. 2022. PMID: 35610444 Free PMC article.
We identified the SARS-CoV-2 RNA in breathing zone of CW, in room air, with the positivity rate of 2.5% at a concentration of 17 10(3) virus genome copies/m(3) air. It also investigates the relationship between local climate conditions [i.e., temperature and relative humid …
We identified the SARS-CoV-2 RNA in breathing zone of CW, in room air, with the positivity rate of 2.5% at a concentration of 17 10(3) virus …
Transcranial and Transcutaneous Stimulation for Pain: What Have We Learned From the COVID-19 Pandemic Shutdown?
Leung A, Alhaqab S, Kunne A, Leung D, Krug P, Golshan S. Leung A, et al. Pain Physician. 2023 May;26(3):E223-E231. Pain Physician. 2023. PMID: 37192245 Free article.

RESULTS: For pre- and posttreatment M-VAS pain scores, mixed-effect analyses for both treatment groups demonstrated significant (P < 0.01) time interactions across all phases. For pretreatment M-VAS pain scores, TMS (n = 27) between-phase analyses indicated a sig

…
RESULTS: For pre- and posttreatment M-VAS pain scores, mixed-effect analyses for both treatment groups demonstrated significant (P &l …
33 results